To the OMX
Announcement No. 36-07 / Copenhagen, 16 October 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget launches Totect™ in the US

- Only FDA-Approved Treatment for Anthracycline Extravasation -

Copenhagen, Denmark – 16 October 2007 – TopoTarget A/S (OMX: TOPO) – has announced that TopoTarget USA, Inc., the US subsidiary of TopoTarget A/S , has made Totect™ available to cancer facilities throughout the US. Totect™ is the only FDA-approved treatment for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding tissue. The company received approval from the US Food and Drug Administration on 6 September 2007.

"*While the number of patients who may be victims of this terrible accident may be low, the cost to these patients and their families, the facilities and the health care system overall can be astronomical,*" said John L. Parsons, president of TopoTarget USA, Inc. "*It is sometimes difficult to prevent an extravasation from occurring, but oncology nurses and physicians now have a way to halt and reverse the devastating effects,*" continued Parsons

More than 500,000 intravenous anthracycline chemotherapy treatments are administered in the US each year.

According to Parsons, an estimated 3,600 oncology departments and centers could benefit from having a Totect™ kit available in the event of an anthracycline extravasation. TopoTarget USA, Inc. has recruited a sales force of 10 oncology specialists. The company also distributes the treatment in Europe under the name Savene™.

Extravasation occurs when intravenously administered chemotherapy drugs accidentally leak out into surrounding tissue. This can occur if a patient is receiving anthracycline chemotherapy intravenously or through a surgically placed port. Extravasation with anthracyclines can lead to severe and cumulative tissue necrosis including serious damage of the surrounding skin, subcutaneous tissue, muscles and nerves. Currently, most patients who have suffered from an anthracycline extravasation need surgery to remove the

damaged tissue and further plastic surgery. In addition, a patient cannot continue with chemotherapy until the damaged area heals.

In the event of an anthracycline extravasation, early detection and rapid treatment can prevent healthy tissue damage – within six hours of the occurrence. In TopoTarget's clinical trials, only one of the 57 evaluable patients required surgery, while 13 had late sequelae at the event, including pain, fibrosis, atrophy and local sensory disturbance, which did not require surgery and could continue with chemotherapy soon after treatment.

For further information on Totect™ visit www.totect.com.

The launch of Totect™ does not change TopoTarget's full-year financial guidance for 2007.

TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22
CONTACT IN THE US:		
Maria Gordon Shydlo or Deanna Decker		
Padilla Speer Beardsley	Telephone	+1 (212) 752-8338

Background information

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding ''Answers for cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug

development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.